Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Name
nihms915227.pdf
Size
1.39 MB
Format
Adobe PDF
Checksum (MD5)
3f3d19646c2cbfd70927be3a1332dbce
Author(s) • • • • • • • • •
Rusan, Maria
Li, Kapsok
Li, Yvonne
Christensen, Camilla L.
Abraham, Brian J.
Kwiatkowski, Nicholas
Buczkowski, Kevin A.
Bockorny, Bruno
Chen, Ting
Li, Shuai
Date Issued
October 2017
Journal
Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Citation
Rusan, Maria et al. “Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.” Cancer Discovery 8, 1 (October 2017): 59–73 © 2017 American Association for Cancer Research
Version
Author's final manuscript
Abstract
Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies. Targeting tumors with kinase inhibitors induces complex adap- tive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones. We show that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models. We propose that targeted therapy induces a state of transcriptional dependency in a subpopulation of cells poised to become drug tolerant, which THZ1 can exploit by blocking dynamic transcriptional responses, promoting remodeling of enhancers and key signaling outputs required for tumor cell survival in the setting of targeted therapy. These findings suggest that the addition of THZ1 to targeted therapies is a promising broad-based strategy to hinder the emergence of drug-resistant cancer cell populations. SIGNIFICANCE: CDK7/12 inhibition prevents active enhancer formation at genes, promoting resistance emergence in response to targeted therapy, and impedes the engagement of transcriptional programs required for tumor cell survival. CDK7/12 inhibition in combination with targeted cancer therapies may serve as a therapeutic paradigm for enhancing the effectiveness of targeted therapies.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/2159-8290.CD-17-0461